Davern Capital Partners, LP
NY, NY · CIK 2003147 · 13F filing filed 2026-02-13
SEC-registered investment adviser since 2025 · limited partnership
- Assets managed$715.1m
- Staff4 · 3 in investment roles
- Main clients (by assets)Sovereign wealth funds 92%, Private funds 8%
- Private funds1 (1 hedge) · $55.1m gross assets
- Main officeNew York, NY
- Websitedaverncapital.com
- Form ADV · 2026-03-27SEC adviser record
- Legal entityDAVERN CAPITAL PARTNERS, LP (US)
$309.3m
reported value
14positions
90.6%in top 10
—no comparable previous quarter
Holdings, Q4 2025
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| PFIZER INC PFE | $50.9m16.44% | First filing |
| REGENERON PHARMACEUTICALS REGN | $40.5m13.08% | First filing |
| BIONTECH SE BNTX | $35.3m11.43% | First filing |
| ROYALTY PHARMA PLC RPRX | $32.5m10.50% | First filing |
| ARGENX SE ARGX | $30.0m9.70% | First filing |
| LEGEND BIOTECH CORP LEGN | $23.0m7.43% | First filing |
| ROIVANT SCIENCES LTD ROIV | $22.3m7.21% | First filing |
| IONIS PHARMACEUTICALS INC IONS | $18.9m6.10% | First filing |
| NATERA INC NTRA | $18.0m5.83% | First filing |
| ELI LILLY & CO LLY | $8.9m2.89% | First filing |
| VIRIDIAN THERAPEUTICS INC VRDN | $8.1m2.63% | First filing |
| MINERALYS THERAPEUTICS INC MLYS | $7.6m2.47% | First filing |
| CG ONCOLOGY INC CGON | $6.7m2.17% | First filing |
| ABIVAX SA ABVX | $6.5m2.11% | First filing |